ELOVL2 mediated stabilization of AR contributes to enzalutamide resistance in prostate cancer
Frontiers in Cell and Developmental Biology · 09.06.2025 · 13
DOI: 10.3389/fcell.2025.1598400 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Cell and Developmental Biology, online erschienen am 09.06.2025. Verfasst von Jinpeng Cen und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
To investigate the molecular mechanisms underlying enzalutamide resistance in castration-resistant prostate cancer (CRPC) and explore potential therapeutic strategies to overcome resistance.
Methods
We conducted comprehensive bioinformatic analysis using LNCaP/enzalutamide-resistant cells to identify key pathways associated with resistance. Functional validation was performed through targeted inhibition of the elongation of very-long chain fatty acid protein 2 (ELOVL2), followed by assays to assess cancer cell proliferation and enzalutamide sensitivity. Mechanistic studies were conducted to evaluate the impact of ELOVL2 on the ubiquitin-proteasome system and AR signaling pathways.
Results
Bioinformatic analysis revealed that activation of fatty acid metabolism, particularly through upregulation of ELOVL2, plays a critical role in driving enzalutamide resistance in PCa. Functional studies demonstrated that targeted inhibition of ELOVL2 significantly suppressed cancer cell proliferation and restored enzalutamide sensitivity in resistant cells. Mechanistically, ELOVL2 facilitates enzalutamide resistance by impairing the ubiquitin-proteasome system, leading to the subsequent activation of AR signaling pathways.
Discussion
Our findings demonstrate that ELOVL2 drives enzalutamide resistance in CRPC by stabilizing AR through inhibition of ubiquitin-proteasome-mediated degradation. Targeting ELOVL2 represents a promising therapeutic strategy to overcome resistance in CRPC, with potential to improve clinical outcomes for patients.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Urology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China.
- Department of Urology, Guangzhou Institute of Cancer Research, the Affiliated Cancer Hospital, Guangzhou Medical University, Guangzhou, Guangdong, China.
- Department of Urology, The Fifth Affiliated Hospital, Southern Medical University, Guangzhou, Guangdong, China.
- Department of Radiotherapy, Guangzhou Institute of Cancer Research, The Affiliated Cancer Hospital, Guangzhou Medical University, Guangzhou, Guangdong, China.
- Department of Urology, The Fourth Affiliated Hospital, Guangzhou Medical University, Guangzhou, Guangdong, China.
- First Clinical Medical College, Southern Medical University, Guangzhou, Guangdong, China.
Zitieren
APA
Cen, J., Guo, J., Zeng, X., Song, X., Ge, S., Chen, M., Li, Q., Yu, Y., Lv, D., & Zhao, S. (2025). ELOVL2 mediated stabilization of AR contributes to enzalutamide resistance in prostate cancer. Frontiers in Cell and Developmental Biology, 13. https://doi.org/10.3389/fcell.2025.1598400
Vancouver
Cen J, Guo J, Zeng X, Song X, Ge S, Chen M, et al. ELOVL2 mediated stabilization of AR contributes to enzalutamide resistance in prostate cancer. Frontiers in Cell and Developmental Biology. 2025;13. doi:10.3389/fcell.2025.1598400
BibTeX
@article{Cen2025,
author = {Cen, Jinpeng and Guo, Jiading and Zeng, Xianzi and Song, Xianlu and Ge, Shengdong and Chen, Mingkun and Li, Qianyi and Yu, Yuzhong and Lv, Daojun and Zhao, Shanchao},
title = {ELOVL2 mediated stabilization of AR contributes to enzalutamide resistance in prostate cancer},
journal = {Frontiers in Cell and Developmental Biology},
year = {2025},
volume = {13},
doi = {10.3389/fcell.2025.1598400}
}
EUVIMED